In July 2022, we partnered with CHAI to execute a volume guarantee agreement with Wondfo to make its WHO prequalified HIV self-test available for $1.
Through this partnership, Wondfo agreed to launch its newly prequalified test at $1 for public sector purchasers in low- and middle-income countries. The price is over 30 per cent below the current lowest-priced test and 50 per cent lower than the most widely used test. This makes Wondfo’s HIV self-test the most affordable World Health Organization (WHO) prequalified HIV self-test on the market.
Lives changed: Estimates for test uptake and linkage to care are based on a meta-analysis by Njau et al. Average HIV positivity rates for Africa reported by UNAIDS were applied to estimate people living with HIV identified through testing.
Money saved: Impact is based on comparing the negotiated price to the expected lowest priced equivalent HIV self-test.
Markets shaped: We work with partners, including donors, procurers and ministries of health, to track changes in health markets where our investments are supporting access to products. We monitor for changes to policy, procurement practices and supplier movement, all of which affect markets and contribute to the long-term sustainability of impact.
UNAIDS estimates that approximately 6.1 million of the 37.7 million people living with HIV in 2020 did not know their status.
Self-testing can play an important role in closing the gap between the number of people living with HIV and those who know their HIV status. People who are undiagnosed are not on treatment, meaning they are at risk of passing the virus on.
For people not infected but at high risk, testing is the first step in accessing prevention interventions such as pre-exposure prophylaxis (PrEP).
Benefits of self-testing include: